Astellas Pharma announced on May 29, 2026, the resignation of an officer and the partial withdrawal of resolutions at the shareholders’ meeting. Following the resignation of Outside Director Andreas Busch, the number of director candidates has been revised to 6.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4503","jir_company_name":"Astellas Pharma Inc.","jir_importance":"\u2605\u2605\u2606\u2606\u2606","jir_publication_date":"2026-05-29","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/05\/4503-20260529-01.pdf","jir_short_summary":"Astellas Pharma announced on May 29, 2026, the resignation of an officer and the partial withdrawal of resolutions at the shareholders' meeting. Following the resignation of Outside Director Andreas Busch, the number of director candidates has been revised to 6.","jir_summary":"### Changes in Executive Personnel and Shareholders' Meeting Resolutions\nAstellas Pharma announced on May 29, 2026, that Outside Director Andreas Busch had resigned. Consequently, the company withdrew some of the agenda items scheduled for the 21st Annual Shareholders' Meeting on June 19, 2026, and revised the number of director candidates from 7 to 6. The reason for the change was due to the candidate's withdrawal, and the resolution contents were amended accordingly.\n\n### Shareholders' Meeting Agenda and Future Outlook\nFollowing the revision, the number of director candidates is 6, with 4 current officers and 2 outside director candidates. The revised composition still meets the statutory and articles of incorporation requirements for the number of directors, totaling 10 members (7 men, 3 women). These personnel changes aim to maintain and strengthen corporate governance.","jir_financial_highlights":"","jir_category":"","jir_hashtags":"#AstellasPharma, #IR, #JapanStocks","jir_key_figures":"Number of director candidates: 6 (previously 7)\nTerminating officer: Andreas Busch\nShareholders' Meeting date: June 19, 2026","jir_meta_title":"\u3010Astellas Pharma\u3011Resignation of Officers and Resolution Amendments\uff5cMay 2026","jir_meta_description":"Astellas Pharma announced on May 29, 2026, the resignation of officers and the partial withdrawal of resolutions at the shareholders' meeting. An overview of personnel changes and upcoming plans is provided.","jir_og_title":"\u3010Astellas Pharma\u3011Officer Resignation and Resolution Amendments\uff5cMay 2026","jir_og_description":"Astellas Pharma announced officer resignations and partial withdrawal of agenda items for the shareholders' meeting. An overview of the future governance structure and shareholder meeting is provided.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":6911,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"general_ir","footnotes":""},"sector":[],"importance":[],"class_list":["post-55611","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n